TITLE

Here come the drugs

PUB. DATE
April 2004
SOURCE
U.S. Catholic;Apr2004, Vol. 69 Issue 4, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the free antiretroviral drugs given by the Catholic Church to South Africans infected with HIV and AIDS. Number of South Africans infected; Plan for the church-run projects for the drugs; Statement from Bishop Kevin Dowling about the proposed antiretroviral drug program from the South African government.
ACCESSION #
12916794

 

Related Articles

  • Cocktail all in one. Kuhr, Fred // Advocate;1/17/2006, Issue 954, p44 

    The article addresses the problems associated with the use of the active antiretroviral therapy to treat HIV. By mid-1990s two new classes of anti-HIV drugs were introduced, one with protease inhibitors was introduced in December 1995 and other one with nonnucleoside reverse transcriptase...

  • Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Zhiqing Zhang; Shaowei Li; Ying Gu; Ningshao Xia // International Journal of Molecular Sciences;Nov2016, Vol. 17 Issue 11, p1901 

    Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment does not cure HIV-1 infection. Furthermore,...

  • Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)—Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens. Domingo, Pere; Cabeza, Maria Carmen; Pruvost, Alain; Salazar, Juliana; del Mar Gutierrez, Maria; Mateo, Maria Gracia; Domingo, Joan C.; Fernandez, Irene; Villarroya, Francesc; Muñoz, Jessica; Vidal, Francesc; Baiget, Montserrat // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p1033 

    Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)- associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels...

  • Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. Papasavvas, Emmanouil; Kostman, Jary R.; Mounzer, Karam; Grant, Robert M.; Gross, Robert; Gallo, Cele; Azzoni, Livio; Foulkes, Andrea; Thiel, Brian; Pistilli, Maxwell; Mackiewicz, Agnieszka; Shull, Jane; Montaner, Luis J. // PLoS Medicine;Dec2004, Vol. 1 Issue 3, p218 

    Background Approaches to limiting exposure to antiretroviral therapy (ART) drugs are an active area of HIV therapy research. Here we present longitudinal follow-up of a randomized, open-label, single-center study of the immune, viral, and safety outcomes of structured therapy interruptions (TIs)...

  • Tenofovir and Nephrotoxicity. Joshi, Amit; Kraus, Mark // Kidney;Nov/Dec2005, Vol. 14 Issue 6, p255 

    The article provides information on the development of antiretroviral drug tenofovir for the treatment of HIV/AIDS. Tenofovir is an acyclic nucleoside phosphonate in the class of nucleotide reverse transcriptase inhibitors. The drug interrupts DNA synthesis by terminating the elongation of the...

  • Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, Víctor; Cartón, José Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378 

    To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (≤200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral...

  • Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. Van Zyl, Gert U.; Liu, Tommy F.; Claassen, Mathilda; Engelbrecht, Susan; de Oliveira, Tulio; Preiser, Wolfgang; Wood, Natasha T.; Travers, Simon; Shafer, Robert W. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Objectives: South Africa’s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy. Cameron, D. William; da^Silva, Barbara A.; Arribas, Jose R.; Myers, Robert A.; Bellos, Nicholaos C.; Gilmore, Norbert; King, Martin S.; Bernstein, Barry M.; Brun, Scott C.; Hanna, George J. // Journal of Infectious Diseases;7/15/2008, Vol. 198 Issue 2, p234 

    Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus either lopinavir/ritonavir (n = 104) or efavirenz (n = 51). Lopinavir/ritonavir-treated subjects demonstrating 3 consecutive monthly HIV-1 RNA levels <50 copies/mL started lopinavir/ritonavir monotherapy. In...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics